Patents Assigned to Wyeth
  • AVIAN INFLUENZA VIRUSES, VACCINES, COMPOSITIONS, FORMULATIONS, AND METHODS
    Publication number: 20080118531
    Abstract: A vaccine composition and method which is effective in preventing or ameliorating Avian Influenza Virus infection is set forth herein. The vaccine contains at least two inactivated strains of avian influenza virus, wherein the combined hemagglutinin (HA) total is at least about 200 HA/dose of the vaccine composition, and wherein each of the strains presents at least about 128 HA/dose, and further wherein one of the strains has the same HA subtype as that of a challenge virus, and wherein at least one of the strains has a different NA subtype than the challenge virus.
    Type: Application
    Filed: April 18, 2007
    Publication date: May 22, 2008
    Applicants: Wyeth, St. Jude Children's Research Hospital
    Inventors: Erich Hoffmann, Scott L. Krauss, Mahesh Kumar, Richard J. Webby, Robert G. Webster
  • QS-21 and IL-12 as an adjuvant combination
    Patent number: 7374751
    Abstract: Adjuvant compositions comprising an effective amount IL-12 and QS-21 are disclosed. Immunogenic, vaccine and pharmaceutical compositions comprising a mixture of antigen and an adjuvant composition comprising an effective amount of IL-12 and QS-21 are also disclosed. These compositions elicit functional cell-mediated and humoral immune responses against at least one antigen. Methods of using the disclosed compositions are also disclosed.
    Type: Grant
    Filed: June 21, 2001
    Date of Patent: May 20, 2008
    Assignee: Wyeth Holdings Corporation
    Inventor: Gerald E. Hancock
  • Processes for the preparation of aminoethoxybenzyl alcohols
    Patent number: 7375251
    Abstract: The present invention provides processes and intermediates for the preparation of aminoethoxybenzyl alcohols of Formula I useful in the production of pharmaceutically useful compounds
    Type: Grant
    Filed: January 11, 2006
    Date of Patent: May 20, 2008
    Assignee: Wyeth
    Inventors: Pietro Allegrini, Giuseppe Barreca, Giorgio Soriato
  • Methods for the Preparation of {2-[(8,9)-Dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} Phosphonic Acid and Esters Thereof
    Publication number: 20080114165
    Abstract: The present invention provides methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid, and esters thereof.
    Type: Application
    Filed: January 18, 2008
    Publication date: May 15, 2008
    Applicant: WYETH
    Inventors: Bogdan WILK, Galina VID, Weiguo LIU, Xinxu SHI
  • AZAINDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
    Publication number: 20080114023
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: November 16, 2007
    Publication date: May 15, 2008
    Applicant: Wyeth
    Inventors: Ronald Charles BERNOTAS, Derek Cecil Cole, William Joseph Lennox
  • Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
    Publication number: 20080114050
    Abstract: Pyrrole-oxindole derivatives useful as progesterone receptor antagonists, and methods for preparing the same, are provided. Pharmaceutical compositions containing these derivatives are described, as is the use thereof in contraception and hormone-related conditions.
    Type: Application
    Filed: November 16, 2007
    Publication date: May 15, 2008
    Applicant: Wyeth
    Inventors: Andrew Fensome, Casey McComas, Edward Melenski, Michael Marella, Jay Wrobel, Gary Grubb
  • High-dose, long-lasting ectoparasiticide for extended control
    Publication number: 20080112993
    Abstract: The present invention provides a topical, high-dose, long-acting ectoparasiticide composition effective for protecting against ectoparasite infestation in a warm-blooded animal for a period of greater than about 6 weeks. Also provided is a method for the extension of the duration of activity of an ectoparasitcide.
    Type: Application
    Filed: August 30, 2007
    Publication date: May 15, 2008
    Applicant: Wyeth
    Inventors: Robert Bruce Albright, Shobhan Shashikant Sabnis, Larry A. Kraft, Susan Holzmer, Robert Alan Pollet, Ramune Marija Cobb
  • 7-Aryl 1,5-Dihydro-4,1-Benzoxazepin-2(3H)-One Derivatives and Their Use As Progesterone Receptor Modulators
    Publication number: 20080113964
    Abstract: This invention provides progesterone receptor modulators having the structure: wherein R1 to R7, X, and Q are as defined in the specification; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 28, 2007
    Publication date: May 15, 2008
    Applicant: Wyeth
    Inventors: Puwen Zhang, Jay Edward Wrobel, Eugene Anthony Terefenko, Jeffrey Curtis Kern
  • Estrogen receptor ? regulated gene expression, related assays and therapeutics
    Patent number: 7371207
    Abstract: A plurality of genes modulated by estrogen or other agents, such as hormones or combinations of hormones, in various types of tissue is described. One embodiment of the disclosure relates to a plurality of genes, which demonstrates certain patterns of expression differing qualitatively or quantitatively, with and without exposure to estrogen and/or other hormone compositions. Methods of using these genes in identifying candidate agents that exert at least some of the biological effects of estrogen and/or other hormone, and pharmaceuticals and related therapies also is disclosed. The use of the plurality of genes in methods of monitoring, in gene chips and in kits also is disclosed.
    Type: Grant
    Filed: April 10, 2003
    Date of Patent: May 13, 2008
    Assignee: Wyeth
    Inventors: Scott Alan Jelinsky, Heather Anne Harris, Eugene Lee Brown, Mark James Evans, Donald Edward Frail
  • GLYCOLYSIS-INHIBITING SUBSTANCES IN CELL CULTURE
    Publication number: 20080108106
    Abstract: An improved system for large scale production of proteins and/or polypeptides in cell culture is provided. In accordance with the present invention, cells expressing the protein or polypeptide of interest are grown in media that comprise a glycolysis-inhibiting substance. Additionally and/or alternatively, cells expressing the protein or polypeptide of interest are grown in media in which glutamine is limited. The use of such a system allows high levels of protein or polypeptide production and lessens accumulation of undesirable metabolic waste products such as lactate. Proteins and polypeptides expressed in accordance with the present invention may be advantageously used in the preparation of pharmaceutical, immunogenic, agricultural or other commercial compositions.
    Type: Application
    Filed: November 2, 2007
    Publication date: May 8, 2008
    Applicant: Wyeth
    Inventors: Wenge Wang, Yen Luan
  • SUGAR COATINGS AND METHODS THEREFOR
    Publication number: 20080107780
    Abstract: The invention provides sugar-containing compositions suitable for use in coating solid preparations such as tablets, pills, granules and grains. Methods of using such coatings are provided, as are solid dosage forms coated with the compositions. In some embodiments, the methods provide sugar coated tablets comprising conjugated estrogens, and a progestin, for example medroxyprogesterone acetate.
    Type: Application
    Filed: November 5, 2007
    Publication date: May 8, 2008
    Applicant: WYETH
    Inventors: John KRESEVIC, Sheetal KULKARNI, Xiuying LIU, Nizamuddin BAKSH, Robin ENEVER
  • Ion channel modulators
    Patent number: 7368467
    Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.
    Type: Grant
    Filed: March 7, 2005
    Date of Patent: May 6, 2008
    Assignee: Wyeth
    Inventors: Robert Zelle, Vincent P. Galullo, Hormoz Mazdiyasni
  • Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
    Patent number: 7368471
    Abstract: This invention provides compounds of the formula: wherein: X is a chemical bond, —CH2— or —C(O)—; R1 is alkyl, cycloalkyl, —CH2-cycloalkyl, pyridinyl, —CH2-pyridinyl, phenyl or benzyl; R2 is H, alkyl, cycloalkyl, —CH2-cycloalkyl, or perfluoroalkyl; R3 is H, halo, alkyl, perfluoroalkyl, alkoxy, cycloalkyl, —CH2-cycloalkyl, —NH2, or —NO2; R4 is optionally substituted phenyl, benzyl, benzyloxy, pyridinyl, or —CH2-pyridinyl, or the salt or ester forms thereof, as well as methods for using the compounds as inhibitors of plasminogen activator inhibitor-1 (PAI-1) and as therapeutic compositions for treating conditions resulting from fibrinolytic disorders such as deep vein thrombosis and coronary heart disease, and pulmonary fibrosis.
    Type: Grant
    Filed: March 29, 2006
    Date of Patent: May 6, 2008
    Assignee: Wyeth
    Inventors: Hassan Mahmound Elokdah, Geraldine Ruth McFarlane, David Zenan Li, Lee Dalton Jennings, David LeRoy Crandall
  • Benzofuranyl alkanamine derivatives and uses thereof
    Patent number: 7368477
    Abstract: Compounds of formula I or pharmaceutically acceptable salts thereof are provided: wherein each of R1, R1?, R2, R3, R4, n, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.
    Type: Grant
    Filed: April 21, 2006
    Date of Patent: May 6, 2008
    Assignee: Wyeth
    Inventors: Jonathan Laird Gross, Gary Paul Stack, Dahui Zhou, Hong Gao
  • Lyophilization methods and apparatuses
    Publication number: 20080098614
    Abstract: A method and apparatus for optimizing the primary drying step of a lyophilization cycle of a biological or pharmaceutical material. In one aspect, the invention is a method for lyophilizing a material comprising the steps of calculating a designed primary drying cycle for the material based on a product temperature profile for the material and modifying both a chamber pressure and a shelf temperature according to a designed primary drying cycle during a primary drying step. In another aspect, the invention is an apparatus for lyophilizing a material according to a designed primary drying cycle comprising a computer-readable medium, a processor in electrical communication with the computer-readable medium, a chamber pressure module in electrical communication with the processor, and a shelf temperature module in electrical communication with the processor.
    Type: Application
    Filed: October 3, 2007
    Publication date: May 1, 2008
    Applicant: Wyeth
    Inventors: Serguei Tchessalov, Nicholas Warne
  • Avian embryo particulate biomass for the production of virus antigens
    Publication number: 20080102507
    Abstract: The present invention provides a biomass which comprises avian embryonic particles having a particle size of about 0.5 mm to 10.0 mm and the use thereof in a method for the production of virus antigens. Also provided is a method for the preparation of a vaccine useful for the amelioration and prevention of viral disease.
    Type: Application
    Filed: December 28, 2005
    Publication date: May 1, 2008
    Applicant: Wyeth
    Inventor: David L. Wederquist
  • METHODS FOR THE SEPARATION OF STREPTOCOCCUS PNEUMONIAE TYPE 3 POLYSACCHARIDES
    Publication number: 20080102498
    Abstract: The present invention provides improved methods for the reduction or removal of protein impurities from a complex cellular Streptococcus pneumoniae lysate or centrate comprising serotype 3 polysaccharides involving steps relating to post-lysis heating or pH adjustment. In certain methods, the lysate is heated for a time and at a temperature sufficient to denature proteins present in the lysate and cause their aggregation and precipitation. In one embodiment, the lysate is heated to at least 60° C. for at least 30 minutes to cause protein aggregation and precipitation, more particularly about 60° C. to about 70° C. for about 30 to about 50 minutes, and even more particularly about 65° C. for about 40 minutes. In other methods, the pH of the lysate or centrate is increased to at least 8.0 to improve filterability, more particularly about 8.0 to 8.4, and even more particularly about 8.2.
    Type: Application
    Filed: October 9, 2007
    Publication date: May 1, 2008
    Applicant: Wyeth
    Inventors: Brian Bahler, Erik Hughes, Tsu-shun Lee
  • 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
    Patent number: 7365073
    Abstract: Disclosed are certain 3-(heteroaryl)alanine derivatives which bind VLA-4 and inhibit leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: April 29, 2008
    Assignees: Elan Pharmaceuticals, Inc., Wyeth
    Inventors: Andrei W. Konradi, Michael A. Pleiss, Eugene D. Thorsett, Darren B. Dressen, Francine S. Farouz, Christopher Semko, Ying-Zi Xu, Frank Stappenbeck
  • Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines
    Patent number: 7365197
    Abstract: This invention relates to a method for the regioselective synthesis of 4,6,7,8-substituted benzo[g]quinoline-3-carbonitriles and 4,6,7,8-substituted benzo[g]quinazolines as well as intermediates thereof. The compounds derived from this invention are useful for the treatment of a variety of diseases that are a result of deregulation of these PTK's, and more specifically, are anti-cancer agents and are useful for the treatment of cancer in mammals. In addition, the compounds derived from this invention are useful for the treatment of polycystic kidney disease in mammals.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: April 29, 2008
    Assignee: Wyeth
    Inventors: Dan Maarten Berger, Gary Harold Birnberg, Yanong Wang
  • MK2 interacting proteins
    Patent number: 7364870
    Abstract: The present invention relates to uses of proteins that bind MK2 to modulate inflammation. More particularly, the invention relates to uses of proteins that bind MK2 for treating condition that are related to inflammation. The invention is useful for treating inflammatory conditions, particularly those in which a decrease in inflammation would be therapeutically beneficial.
    Type: Grant
    Filed: August 1, 2003
    Date of Patent: April 29, 2008
    Assignee: Wyeth
    Inventors: Yvonne M. Yannoni, Lih-Ling Lin